Literature DB >> 14870881

Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients.

Ruth Mackenzie1, Clifford J Holmes, Suzanne Jones, John D Williams, Nicholas Topley.   

Abstract

Clinical indices of in vivo biocompatibility: The role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Over the past 20 years, studies of the biocompatibility profile of peritoneal dialysis solutions (PDF) have evolved from initial in vitro studies assessing the impact of solutions on leukocyte function to evaluations of mesothelial cell behavior. More recent biocompatibility evaluations have involved assessments of the impact of PDF on membrane integrity and cell function in peritoneal dialysis (PD) patients. The development of ex vivo systems for the evaluation of in vivo cell function, and effluent markers of membrane integrity and inflammation in patients exposed both acutely and chronically to conventional and new PDF will be interpreted in the context of our current understanding of the biology of the dialyzed peritoneum. The available data indicate that exposure of the peritoneal environment to more biocompatible PDF is associated with improvements in peritoneal cell function, alterations in markers of membrane integrity, and reduced local inflammation. These data suggest that more biocompatible PDF will have a positive impact on host defense, peritoneal homeostasis, and the long-term preservation of peritoneal membrane function in PD patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14870881     DOI: 10.1046/j.1523-1755.2003.08809.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  10 in total

1.  Trials (and tribulations) of biocompatible peritoneal dialysis fluids.

Authors:  David W Johnson; Yeoungjee Cho; Fiona G Brown
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

2.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

3.  Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

4.  Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial.

Authors:  Klaus Kratochwill; Michael Boehm; Rebecca Herzog; Katharina Gruber; Anton Michael Lichtenauer; Lilian Kuster; Dagmar Csaicsich; Andreas Gleiss; Seth L Alper; Christoph Aufricht; Andreas Vychytil
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

Review 5.  Is there such a thing as biocompatible peritoneal dialysis fluid?

Authors:  Claus Peter Schmitt; Christoph Aufricht
Journal:  Pediatr Nephrol       Date:  2016-10-08       Impact factor: 3.714

6.  Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid.

Authors:  Rebecca Herzog; Lilian Kuster; Julia Becker; Tobias Gluexam; Dietmar Pils; Andreas Spittler; Manoj K Bhasin; Seth L Alper; Andreas Vychytil; Christoph Aufricht; Klaus Kratochwill
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

7.  Steviol glycosides as an alternative osmotic agent for peritoneal dialysis fluid.

Authors:  Valeria Kopytina; Lucía Pascual-Antón; Nora Toggweiler; Eva-María Arriero-País; Lisa Strahl; Patricia Albar-Vizcaíno; David Sucunza; Juan J Vaquero; Sonja Steppan; Dorothea Piecha; Manuel López-Cabrera; Guadalupe-Tirma González-Mateo
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

8.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28

Review 9.  Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis.

Authors:  Manuel López-Cabrera
Journal:  Adv Med       Date:  2014-01-23

Review 10.  Clinical causes of inflammation in peritoneal dialysis patients.

Authors:  Yeoungjee Cho; Carmel M Hawley; David W Johnson
Journal:  Int J Nephrol       Date:  2014-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.